These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 17996591)
1. Prognostic factors and staging in multiple myeloma. Fonseca R; San Miguel J Hematol Oncol Clin North Am; 2007 Dec; 21(6):1115-40, ix. PubMed ID: 17996591 [TBL] [Abstract][Full Text] [Related]
2. Prognostic features of multiple myeloma. San Miguel JF; García-Sanz R Best Pract Res Clin Haematol; 2005; 18(4):569-83. PubMed ID: 16026738 [TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation. Rajkumar SV; Buadi F Best Pract Res Clin Haematol; 2007 Dec; 20(4):665-80. PubMed ID: 18070712 [TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in multiple myeloma: practicability for clinical practice and future perspectives. Haferlach T; Löffler H Leukemia; 1997 Dec; 11 Suppl 5():S5-9. PubMed ID: 9436931 [TBL] [Abstract][Full Text] [Related]
14. [Contribution to the evaluation of the relationship between angiogenic cytokines, selected biological parameters and prognostic factors in multiple myeloma]. Scudla V; Pika T; Budíková M; Ordeltová M; Minarík J; Zemanová M; Bacovský J; Srovnalík K; Cas Lek Cesk; 2006; 145(12):929-35. PubMed ID: 17323615 [TBL] [Abstract][Full Text] [Related]
15. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count. Perosa F; Minoia C; Favoino E; Prete M; Dammacco F Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035 [TBL] [Abstract][Full Text] [Related]
16. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Kyrtsonis MC; Maltezas D; Tzenou T; Koulieris E; Bradwell AR Semin Hematol; 2009 Apr; 46(2):110-7. PubMed ID: 19389494 [TBL] [Abstract][Full Text] [Related]
17. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425 [TBL] [Abstract][Full Text] [Related]
18. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. Kumar SK; Dingli D; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA Br J Haematol; 2008 Apr; 141(2):205-11. PubMed ID: 18318761 [TBL] [Abstract][Full Text] [Related]
19. NCCN practice guidelines for multiple myeloma. National Comprehensive Cancer Network. Oncology (Williston Park); 1998 Nov; 12(11A):317-51. PubMed ID: 10028515 [No Abstract] [Full Text] [Related]
20. Multiple myeloma: treatment options for an incurable disease. Pandit SR J Assoc Physicians India; 2005 Dec; 53():1060-4. PubMed ID: 16572964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]